Please use this identifier to cite or link to this item:
https://hdl.handle.net/11000/33768
Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real‑world observational study
View/Open: Effectiveness of rituximab vs. ocrelizumab for the treatment.pdf
885,26 kB
Adobe PDF
Share:
This resource is restricted
Title: Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real‑world observational study |
Authors: Alcalá, Carmen Quintanilla-Bordás, Carlos  Gascón, Francisco  Perez-Sempere, Angel  Navarro, Laura Carcelén‑Gadea, María Landete, Lamberto  Mallada, Javier Cañizares, Emmanuel Belenguer, Antonio Carratalá, Sara Domínguez, José Andrés Pérez‑Miralles, Francisco Carlos Gil‑Perotín, Sara Gasqué, Raquel Cubas, Laura Castillo, Jéssica Casanova, Bonaventura  |
Editor: Springer |
Department: Departamentos de la UMH::Medicina Clínica |
Issue Date: 2022 |
URI: https://hdl.handle.net/11000/33768 |
Abstract:
Introduction Ocrelizumab, an antiCD-20 antibody, is the only drug approved to treat patients with primary progressive multiple sclerosis (pwPPMS). Not all candidates receive this treatment due to prescription limitations. Rituximab, another antiCD-20 antibody, has been used off-label in pwPPMS befo... Ver más
|
Keywords/Subjects: Esclerosis múltiple ocrelizumab |
Knowledge area: CDU: Ciencias aplicadas: Medicina |
Type of document: info:eu-repo/semantics/article |
Access rights: info:eu-repo/semantics/closedAccess Attribution-NonCommercial-NoDerivatives 4.0 Internacional |
DOI: https://doi.org/10.1007/s00415-022-10989-0 |
Appears in Collections: Artículos Medicina Clínica
|
???jsp.display-item.text9???